Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis

Multiorgan fibrosis in systemic sclerosis (SSc) accounts for substantial mortality and lacks effective therapies. Lying at the crossroad of TGF-β and TLR signaling, TGF-β–activated kinase 1 (TAK1) might have a pathogenic role in SSc. We therefore sought to evaluate the TAK1 signaling axis in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Bale, Swarna, Verma, Priyanka, Yalavarthi, Bharath, Scarneo, Scott Arthur, Hughes, Philip, Amin, M. Asif, Tsou, Pei-Suen, Khanna, Dinesh, Haystead, Timothy A.J., Bhattacharyya, Swati, Varga, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443806/
https://www.ncbi.nlm.nih.gov/pubmed/37306632
http://dx.doi.org/10.1172/jci.insight.165358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443806/
https://www.ncbi.nlm.nih.gov/pubmed/37306632
http://dx.doi.org/10.1172/jci.insight.165358

Ejemplares similares